Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries

Human Vaccines

Volumn 7, Issue 7, 2011, Pages 734-748

  Giaquinto, Carlo ^a   Dominiak Felden, Geraldine ^b   Van Damme, Pierre ^c   Myint, Tin Tin Htar ^h   Maldonado, Yvonne A ^d   Spoulou, Vana ^e   Mast, T Christopher ^f   Staat, Mary Allen ^g  

^a UNIVERSITY OF PADOVA   (Italy)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

^f MERCK RESEARCH LABORATORIES   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h NONE

Author keywords

Hospitalization; Laboratory; RotaTeq; Rotavirus; Vaccination impact; Vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE;

AUSTRALIA; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE DURATION; DRUG EFFICACY; EMBASE; EMERGENCY WARD; EUROPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HERD IMMUNITY; HOSPITALIZATION; HUMAN; INDUSTRIALIZATION; LABORATORY TEST; MEDLINE; OUTCOME ASSESSMENT; REVIEW; ROTAVIRUS INFECTION; SYSTEMATIC REVIEW; UNITED STATES; VACCINATION; VIRAL GASTROENTERITIS;

ADMINISTRATION, ORAL; AUSTRALIA; EUROPE; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES; VACCINATION; VACCINES, ATTENUATED;

EID: 79960788763     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.7.15511     Document Type: Review

References (84)

1. World Health Organization. State of the art of new vaccines research & development: initiative for vaccine research. Geneva, Switzerland: World Health Organization 2003. Available from: http://www.who.int/vaccine-research/ documents/en/stateofart-excler.pdf
2. Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004; 17:461-9; PMID: 15353966.
3. Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22:476-87; PMID: 16418157.
4. Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine 2006; 24:2732-50; PMID: 16483695.
5. Clark H, Offit P. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004; 33:536-43; PMID: 15354605.
6. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72; PMID: 12737740.
7. Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8; PMID: 8793926.
8. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200:9-15; PMID: 19817620.
9. Parashar UD, Alexander JP, Glass RI. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-13.
10. Mast TC, Walter EB, Bulotsky M, Khawaja SS, DiStefano DJ, Sandquist MK, et al. Burden of childhood rotavirus disease on health systems in the United States. Pediatr Infect Dis J 2010; 29:19-25; PMID: 20135751.
11. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Gentsch JR, Stockman LJ, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008; 122:1235-43; PMID: 19047240.
12. Van Damme P, Giaquinto C, Huét F, Gothefors L, Maxwell M, Van der Wielen M, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe 2004-2005: The REVEAL Study. J Infect Dis 2007; 195:4-16; PMID: 17387650.
13. Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123:393-400; PMID: 19254975.
14. Newall AT, Raina M, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. J Paediatr Child Health 2006; 42:521-7. (Pubitemid 44252523)
15. Giaquinto C, Van Damme P, Huet F, Gothefors L, Wielen Van der M. REVEAL Study Group. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007; 195:36-44; PMID: 17539193.
16. Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter EB. The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009; 9:11; PMID: 19200366. Available from: http://www.biomedcentral.com/1471-2431/9/11.
17. Van der Wielen M, Giaquinto C, Gothefors L, Huelsse C, Huet F, Littmann M, et al. Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract 2010; 11:22; PMID: 20230601. Available from: http://www.biomedcentral.com/1471-2296/11/22.
18. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998; 279:1371-6; PMID: 9582045. Available from: http://jama.ama-assn.org/content/279/17/1371.long
19. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684-97; PMID: 17403839. Available from: http://pediatrics.aappublications.org/cgi/content/full/119/4/684.
20. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID: Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa052664.
21. Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009; 28:345-51; PMID: 19879226.
22. Ruiz-Palacios GM, Pérez-Schael I, Veláquez FR, Abate H, Breuer TH, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID: 16394298; Available from: http://www.nejm.org/doi/fll/10.1056/NEWJMoa052434.
23. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet 2002; 359:431-4; PMID: 11844534.
24. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993; 22:742-6; PMID: 8225751.
25. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700; PMID: 18583958. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5725a6.htm
26. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction - United States 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146-9; PMID: 19847149. Available from: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5841a2.htm
27. Centers for Disease Control and Prevention (CDC). National, state and local area vaccination coverage among children aged 19-35 months - United States 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1171-7; PMID: 20847720. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5936a2.htm?s-cid=mm5936a2-w
28. Preedy VR, Watson RR. Handbook of disease burdens and quality of life measures. New York: Springer 2010; 4:4225.
29. Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev Vaccines 2008; 7:1475-80; PMID: 19053204.
30. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125:199-207; PMID: 20083525.
31. thInternational Conference on Vaccines for Enteric Diseases (VED). 9-11 September 2009. Malaga, Spain.
32. Begué RE, Perrin K. Efficiency of pentavalent rotavirus vaccine (PRV) in primary practice. Pediatric Academic Societies, Annual Meeting. 2-5 May 2009, Baltimore, MD USA.
33. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:208-13; PMID: 20100757.
34. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in belgium: policy and impact. Pediatr Infect Dis J 2011; 30:21-4. PMID: 21183836.
35. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID: 12724479. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa022823.
36. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21:2015-21; PMID: 12706691.
37. Mast TC, Wang F, Glass R, Seeger J. Sustained reduction in 2009 of pediatric rotavirus medical encounters in a national medical claims database after introduction of RotaTeq®, oral pentavalent rotavirus vaccine. 44th National Immunization Conference. 19-22 April 2010; Atlanta, Georgia USA. Abstract 22838.
38. th International Rotavirus Symposium. 2-3 August 2010; Johannesburg, South Africa.
39. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56; PMID: 15484186.
40. Desselberger U, Wolleswinkel-van den Bosch J, Mrukowicz J, Rodrigo C, Giaquinto C, Vesikari T. Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J 2006; 25(1 Suppl):30-41; PMID: 16397427.
41. Sanzone AM, Begué RE. Rotavirus hospital surveillance in the era of immunization. Open Vaccine J 2010; 3:89-95. Available from: http://www.bentham.org/open/tovacj/articles/V003/89TOVACJ.pdf
42. Tate JE, Mutuc JD, Panozzo CA, Payne DC, Cortese MM, Cortes JE, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30:30-4. PMID: 21183838.
43. Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, Esposito DH, et al. Uptake, impact and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011; 30:56-60. PMID: 21183842.
44. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. Pediatr Infect Dis J 2011; 30:25-9. PMID: 21183837.
45. th European Meeting of the Society for Medical Decision Making. 30 May-2 June 2010-Innsbruck, Austria.
46. Van Effelterre T, Soriano-Gabarró M, Debrus S, Claire Newbern E, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010; 138:884-97; PMID: 20028612.
47. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201:1617-24; PMID: 20402596.
48. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126:506-12; PMID: 20732946.
49. Bresee JS, Galss RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17:2207-22; PMID: 10403588.
50. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361:2226-34; PMID: 12842379.
51. Jiang V, Jiang B, Tate J, Parashar UD, Patel MM. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccines 2010; 6; PMID: 20622508.
52. Tate JE, Patel MM, Steele AD, Gentsch JR, Payne DC, Cortese MM, et al. Global impact of rotavirus vaccines. Expert Rev Vaccines 2010; 9:395-407; PMID: 20370550.
53. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51; PMID: 19491186. Available from: http://jama.amaassn.org/content/301/21/2243.long
54. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 4-8 May 2010; Nice, France.
55. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14; PMID: 20692030.
56. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98. PMID: 20107214.
57. Munos MK, Walker CL, Black RE. The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol 2010; 39:56-62; PMID: 20348127.
58. th Annual Conference on Vaccine Research; Baltimore, MD; April 27-29, 2009; Poster 66.
59. Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006; 134:908-16; PMID: 16650331.
60. Payne DC, Szilagyi PG, Staat MA, Edwards KM, Gentsch JR, Weinberg GA, et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009; 28:948-53; PMID: 19859013.
61. Zeller M, Rahman M, Heylen E, De Coster S, De Vos S, Arijs I, Novo L, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28:7507-13; PMID: 20851085.
62. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
63. th Réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI). 3-4 December 2009; Paris, France.
64. th Annual Meeting of the Infections Diseases Society of America (IDSA). 29 October-1 November 2009; Philadelphia, PA USA.
65. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009; 16:382-6; PMID: 19158283.
66. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465-71; PMID: 19581260.
67. th Annual Meeting of the World Society for Pediatric Infectious Diseases (WSPID). 18-22 November 2009; Buenos Aires, Argentina.
68. Payne DC, Edwards KM, Staat MA, Szilagyi PG, Gentsch JR, Curns AT, et al. Decline in rotavirus hospitalizations in 3 US counties after introduction of rotavirus vaccine. Pediatric Academic Societies, Annual Meeting 2-5 May 2009; Baltimore, MD USA.
69. th Annual Meeting of the Infectious Disease Society of America (IDSA). 29 October-1 November 2009; Philadelphia, PA USA.
70. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
71. th Annual Meeting of the Infectious Disease Society of America (IDSA). 29 October-1 November 2009; Philadelphia, PA USA.
72. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
73. th Annual Meeting of the Infectious Diseases Society of America (IDSA). October 29-November 1 2009; Philadelphia, PA USA.
74. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
75. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
76. th Annual Meeting of the Infectious Diseases Society of America (IDSA). 25-28 October 2008; Washington, DC USA.
77. th Annual Meeting of the Infections Diseases Society of America (IDSA). 29 October-1 November 2009; Philadelphia, PA USA.
78. Staat M, Rice M, Payne D, Bresee J, Mast TC, Donauer S, et al. Estimating the burden of rotavirus hospitalizations and monitoring trends using capture-recapture methods. Pediatric Academic Societies, Annual Meeting. 2-5 May 2009; Baltimore, MD USA.
79. Custodio H, Halstead D, Maraqa N, Mckitrick P, Rathore M. Decrease in rotavirus infection and hospitalization in northeast Florida after the introduction of rotavirus vaccine. Pediatric Academic Societies, Annual Meeting 2-5 May 2009; Baltimore, MD USA.
80. Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010; 28:754-8; PMID: 19896451.
81. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Erratum in: Med J Aust 2010; 192:525. Med J Aust 2009; 191:157-60; PMID: 19645646.
82. th International Conference on Vaccines for Enteric Diseases (VED). 9-11 September 2009; Malaga, Spain.
83. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 9-13 June 2009; Brussels, Belgium.
84. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010; 29:319- 23; PMID: 19935446.